Search

Your search keyword '"Nehlmeier, Inga"' showing total 211 results

Search Constraints

Start Over You searched for: Author "Nehlmeier, Inga" Remove constraint Author: "Nehlmeier, Inga"
211 results on '"Nehlmeier, Inga"'

Search Results

1. Omicron subvariant BA.5 efficiently infects lung cells

6. Macrophage- and CD4+ T cell-derived SIV differ in glycosylation, infectivity and neutralization sensitivity

7. Virological Traits of the SARS-CoV-2 BA.2.87.1 Lineage

9. Author Reply to Peer Reviews of Macrophage- and CD4+ T cell-derived SIV differ in glycosylation, infectivity and neutralization sensitivity

11. Macrophage- and CD4+ T cell-derived SIV differ in glycosylation, infectivity and neutralization sensitivity.

13. Polyvalent Glycomimetic-Gold Nanoparticle Conjugates reveal effects of glycan display on Multivalent Lectin-Glycan Interactions

14. Macrophage- and CD4+T cell-derived SIV differ in glycosylation, infectivity and neutralization sensitivity

18. Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3

21. TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection

23. Inside Back Cover Image, Volume 95, Number 1, January 2023

25. TMPRSS2 is essential for SARS-CoV-2 Beta and Omicron infection

26. The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages

27. The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant

28. Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1

29. Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75

31. Native and activated antithrombin inhibits TMPRSS2 activity and SARS‐CoV‐2 infection

33. Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy

34. SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination

35. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

36. Native and activated antithrombin inhibits TMPRSS2 activity and SARS‐CoV‐2 infection.

37. The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic

38. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination

40. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

41. Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and BNT162b2 vaccination

42. Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination

43. Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination

46. Glycan-Gold Nanoparticles as Multifunctional Probes for Multivalent Lectin–Carbohydrate Binding: Implications for Blocking Virus Infection and Nanoparticle Assembly

47. Probing Multivalent Lectin-Carbohydrate Binding via Multifunctional Glycan-Gold Nanoparticles: Implications for Blocking Virus Infection

50. Evidence for influenza B virus hemagglutinin adaptation to the human host: high cleavability, acid-stability and preference for cool temperature

Catalog

Books, media, physical & digital resources